Table 4.
Neurological outcomes.
| All Patients n = 213 |
Open Surgery n = 110 (51.6%) |
Robotic Surgery n = 103 (48.4%) |
|
|---|---|---|---|
| MFGA-PIS | |||
| CSR | 17 (8%) | 12 (10.9%) | 5 (4.9%) |
| MM | 73 (34.3%) | 47 (42.7%) | 26 (25.2%) |
| PR | 2 (0.9%) | 1 (0.9%) | 1 (0.9%) |
| I | 93 (43.7%) | 63 (57.3%) | 30 (29.1%) |
| U | 30 (14.1%) | 16 (14.5%) | 14 (13.6%) |
| W | 14 (6.6%) | 3 (2.7%) | 11 (10.7%) |
| E | 3 (1.4%) | 2 (1.8%) | 1 (0.9%) |
| Preoperative MGC score | 7.1 (8.1) | 7 (8.2) | 7.1 (8.1) |
| Postoperative MGC score | 2.8 (5.5) | 2.8 (5.6) | 2.8 (5.5) |
| Preoperative MG-ADL | 3.8 (3.3) | 3.9 (3.3) | 3.8 (3.3) |
| Median postoperative | |||
| MG-ADL | 1.8 (2.8) | 1.8 (2.9) | 1.8 (2.8) |
| Postoperative reduction of steroid | 117 (54.9%) | 70 (63.6%) | 47 (45.6%) |
| Postoperative reduction of pyridostigmine | 91 (42.7%) | 53 (48.2%) | 38 (36.9%) |
| Postoperative reduction of MG symptoms | 146 (68.5%) | 77 (70%) | 69 (67%) |
MGFA-PIS: Myasthenia Gravis Foundation of America Post-Intervention Score; MGC score: Myasthenia Gravis Composite score; MG-ADL: Myasthenia Gravis Activities of Daily Living; CSR: complete symptom remission; MM: minimal manifestation; PR: pharmacologic remission; I: improved; U: unchanged; W: worse; E: exacerbation. Statistics: mean (SD) or frequency (%).